WO2023122731A3 - A live attenuated mumps virus-based sars-cov-2 vaccine - Google Patents

A live attenuated mumps virus-based sars-cov-2 vaccine Download PDF

Info

Publication number
WO2023122731A3
WO2023122731A3 PCT/US2022/082244 US2022082244W WO2023122731A3 WO 2023122731 A3 WO2023122731 A3 WO 2023122731A3 US 2022082244 W US2022082244 W US 2022082244W WO 2023122731 A3 WO2023122731 A3 WO 2023122731A3
Authority
WO
WIPO (PCT)
Prior art keywords
cov
vaccine
sars
muv
live attenuated
Prior art date
Application number
PCT/US2022/082244
Other languages
French (fr)
Other versions
WO2023122731A2 (en
Inventor
Jianrong Li
Mijia LU
Prosper N. BOYAKA
Mark PEEBLES
Yuexiu ZHANG
Mahesh K C
Original Assignee
Ohio State Innovation Foundation
Research Institute At Nationwide Children's Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation, Research Institute At Nationwide Children's Hospital filed Critical Ohio State Innovation Foundation
Publication of WO2023122731A2 publication Critical patent/WO2023122731A2/en
Publication of WO2023122731A3 publication Critical patent/WO2023122731A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18741—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18751—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Abstract

Disclosed herein are live attenuated recombinant mumps virus (rMuV)-based SARS-CoV-2 vaccines and methods for vaccinating a subject for COVID-19 using the disclosed vaccines. Advantages of MuV-based SARS-CoV-2 vaccine include a great safety record, ideal for infants and children, overcomes the pre-existing MuV immunity, no integration to host DNA, high expression level, high efficacy, long term (life-long) immunity, excellent genetic stability, well-established GMP vaccine manufacture, a quadrivalent vaccine for SARS-CoV-2, MeV, MuV, and rubella virus, protection against SARS-CoV-2 variants, human clinical trial experience, and the MMR vaccine is lyophilized and stored at refrigerator temperatures both before and after it is reconstituted, greatly reducing its cost.
PCT/US2022/082244 2021-12-22 2022-12-22 A live attenuated mumps virus-based sars-cov-2 vaccine WO2023122731A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163292857P 2021-12-22 2021-12-22
US63/292,857 2021-12-22

Publications (2)

Publication Number Publication Date
WO2023122731A2 WO2023122731A2 (en) 2023-06-29
WO2023122731A3 true WO2023122731A3 (en) 2023-08-31

Family

ID=86903802

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/082244 WO2023122731A2 (en) 2021-12-22 2022-12-22 A live attenuated mumps virus-based sars-cov-2 vaccine

Country Status (1)

Country Link
WO (1) WO2023122731A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070258997A1 (en) * 1999-08-02 2007-11-08 Wyeth Rescue of mumps virus from CDNA
WO2021222228A1 (en) * 2020-04-27 2021-11-04 Ohio State Innovation Foundation A live attenuated measles virus vectored vaccine for sars-cov-2
CN113773372A (en) * 2021-08-15 2021-12-10 北京科兴中维生物技术有限公司 Recombinant protein and preparation method and application thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070258997A1 (en) * 1999-08-02 2007-11-08 Wyeth Rescue of mumps virus from CDNA
WO2021222228A1 (en) * 2020-04-27 2021-11-04 Ohio State Innovation Foundation A live attenuated measles virus vectored vaccine for sars-cov-2
CN113773372A (en) * 2021-08-15 2021-12-10 北京科兴中维生物技术有限公司 Recombinant protein and preparation method and application thereof

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
DATABASE Uniprot [online] UniprotKB; ANONYMOUS : "SubName: Full=Surface glycoprotein {ECO:0000313|EMBL:QQZ31258.1};", XP093096856 *
FATHIZADEH ET AL.: "SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review", INT J BIOL MACROMOL, vol. 188, October 2021 (2021-10-01), pages 740 - 750, XP086776333, [retrieved on 20210814], DOI: 10.1016/j.ijbiomac.2021.08.076 *
HUANG ET AL.: "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", LANCET, vol. 395, no. 10223, 2020, pages 497 - 506, XP086050317, DOI: 10.1016/S0140-6736(20)30183-5 *
LU ET AL.: "Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding", LANCET, vol. 395, no. 10224, 2020, pages 565 - 574, XP055740615, DOI: 10.1016/S0140-6736(20)30251-8 *
MENACHERY ET AL.: "A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence", NAT MED, vol. 21, no. 12, 2015, pages 1508 - 1513, XP037143869, DOI: 10.1038/nm.3985 *
TAO ET AL.: "The biological and clinical significance of emerging SARS-CoV-2 variants", NAT REV GENET, vol. 22, no. 12, 2021, pages 757 - 773, XP037618992, [retrieved on 20210917], DOI: 10.1038/s41576-021-00408-x *
WHO WHO WHO: "Classification of omicron B.1.1.529 : SARS-Cov-2 variant of concern ", WORLD HEALTH ORGANISATION, 26 November 2021 (2021-11-26), XP093024407 *
XIA: "Domains and Functions of Spike Protein in SARS-Cov-2 in the Context of Vaccine Design", VIRUSES, vol. 13, no. 1, January 2021 (2021-01-01), pages 109, XP055825941, DOI: 10.3390/v13010109 *
XU ET AL.: "Prime-Boost Vaccination with Recombinant Mumps Virus and Recombinant Vesicular Stomatitis Virus Vectors Elicits an Enhanced Human Immunodeficiency Virus Type 1 Gag- Specific Cellular Immune Response in Rhesus Macaques", J VIROL, vol. 83, no. 19, 2009, pages 9813 - 9823, XP002677825, DOI: 10.1128/JVI.00550-09 *
ZHANG YUEXIU, MIJIA LU, K C MAHESH, EUNSOO KIM, MOHAMED M. SHAMSELDIN, CHENGJIN YE, PIYUSH DRAVID, MICHELLE CHAMBLEE, JUN-GYU PAR: "A highly efficacious live attenuated mumps virus–based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike ", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, 27 July 2022 (2022-07-27), pages 1 - 12, XP093021457, ISSN: 0027-8424 *
ZHOU ET AL.: "A Novel Bat Coronavirus Closely Related to SARSCoV-2 Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein", CURR BIOL, vol. 30, no. 11, 2020, pages 2196 - 2203, XP086173147, DOI: 10.1016/j.cub.2020.05.023 *

Also Published As

Publication number Publication date
WO2023122731A2 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
Freer et al. Varicella-zoster virus infection: natural history, clinical manifestations, immunity and current and future vaccination strategies
Gupta et al. Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
MX2023000411A (en) Sars-cov-2 and influenza combination vaccine.
Kamboj et al. Vaccination of the stem cell transplant recipient and the hematologic malignancy patient
WO2008026225A3 (en) A vaccine for chikungunya virus infection
MX2019003682A (en) Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same.
JP2014520117A5 (en)
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
WO2022140364A3 (en) African swine fever (asf) virus vaccines
WO2014145951A3 (en) Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
MX2018015506A (en) Vaccine against infectious bronchitis virus.
ZA201707985B (en) Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
Triglav et al. Vaccination indications and limits in the elderly
WO2023122731A3 (en) A live attenuated mumps virus-based sars-cov-2 vaccine
Tsang Vaccination recommendations for the hematology and oncology and post–stem cell transplant populations
Wang et al. A suicidal DNA vaccine expressing the fusion protein of peste des petits ruminants virus induces both humoral and cell-mediated immune responses in mice
Scully The age of vaccines
MX2022004869A (en) Chikungunya virus-like particle vaccine and methods of using the same.
JP2016514114A5 (en)
임종우 et al. Poly (Amino Acid) based adjuvants containing squalene for enhancing both cell-mediated and humoral immune responses against influenza virus
GT201400199A (en) VIRUS OF THE MODIFIED MAREK'S DISEASE AND VACCINES PREPARED WITH HIM
Soumya et al. Herd immunity
WO2022256637A3 (en) Synthetic dna vaccine immunogenic improvements
PH12015500740A1 (en) Vaccination against japanese encephalitis, measles, mumps and rubella

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22912736

Country of ref document: EP

Kind code of ref document: A2